| Dana E Rademacher, MD | |
|
1212 Well St, Onalaska, WI 54650-2668 | |
| (608) 392-9678 | |
| Not Available |
| Full Name | Dana E Rademacher |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 32 Years |
| Location | 1212 Well St, Onalaska, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033100086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 39742 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | La crosse, WI | Hospital |
| Winona Health Services | Winona, MN | Hospital |
| Mayo Clinic Hlth Systm Franciscan Hlthcare Sparta | Sparta, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | 0345152443 | 419 |
| Winona Health Services | 8527977420 | 101 |
News Archive
Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine studying how pathogens affect fetal development and change the outcome of pregnancy.
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20031110000684 |
News Archive
Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine studying how pathogens affect fetal development and change the outcome of pregnancy.
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841278637 PECOS PAC ID: 0345152443 Enrollment ID: O20100506000523 |
News Archive
Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine studying how pathogens affect fetal development and change the outcome of pregnancy.
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine studying how pathogens affect fetal development and change the outcome of pregnancy.
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dana E Rademacher, MD Po Box 1510, Eau Claire, WI 54702-1510 Ph: (715) 838-5222 | Dana E Rademacher, MD 1212 Well St, Onalaska, WI 54650-2668 Ph: (608) 392-9678 |
News Archive
Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine studying how pathogens affect fetal development and change the outcome of pregnancy.
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.
› Verified 4 days ago